Arbitrator Rules For India's Glenmark In Three-Party HIV Drug Dispute
This article was originally published in PharmAsia News
Executive Summary
An international arbitrator ruled for Glenmark Pharmaceuticals in a dispute concerning the rights to market its diarrhea drug for patients on antiretroviral therapy, clearing the Indian drug maker to sell its crofelemer in 140 countries.